Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Telegram Restored on Apple App Store After Temporary Removal 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
NEW YORK, April 09, 2018 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of investors who purchased Henry Schein, Inc. ("Henry Schein") (NASDAQ:HSIC) securities between March 7, 2013 and February 12, 2018.
Click here to learn about the case: http://www.wongesq.com/pslra-c/henry-schein-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) Henry Schein was engaging in unethical, anti-competitive behavior through agreements with Benco Dental Supply Company and Patterson Companies, Inc., in violation of United States antitrust laws; (2) Henry Schein engaged in such behavior, in part, to help maintain profitability in a consolidating health care industry; (3) these violations of U.S. antitrust laws would result in heightened scrutiny by the federal government and a lawsuit filed by the Federal Trade Commission (“FTC”); (4) Henry Schein failed to maintain adequate internal controls; and (5) as a result, defendants' statements about Henry Schein’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Henry Schein you have until May 7, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-c/henry-schein-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
